There is a newer version of the record available.

Published June 1, 2021 | Version 1.3
Preprint Open

Genomics of Human Respiratory Syncytial Virus Vaccine Attenuation

Authors/Creators

  • 1. Swiss Institute of Bioinformatics, Vital-IT Group, Université de Lausanne, Bâtiment Amphipôle, 1015 Lausanne, Switzerland
  • 2. Hôpitaux Universitaires de Genève, Service des Maladies Infectieuses, Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland
  • 3. Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
  • 4. Institute for Medicine and Public Health, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 450, Nashville, Tennessee 37203, USA
  • 5. Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; Swiss Institute of Bioinformatics, Vital-IT Group, Université de Lausanne, Bâtiment Amphipôle, 1015 Lausanne, Switzerland

Description

(Submitted)

The human orthopneumovirus (HRSV) is a major cause of lower respiratory tract infection in children
worldwide. Despite decades of efforts, no vaccine against HRSV is commercially available, although
research has produced sequence data from strains considered potential vaccines ("vaccine candidates").
In this work, we report genomic positions in which the genotype depends on whether the sequence is
wild-type or vaccine candidate – taking into account all the publicly available HRSV sequence data. These
positions and the mutations they harbour are different from the ones already known to attenuate the
virus, and thus may contribute to the effort towards producing a live attenuated vaccine against HRSV.

Notes

Supplementary data cited according to Instructions for Authors

Files

manuscript.pdf

Files (142.6 kB)

Name Size Download all
md5:71fa37490acf4613f2672194d0b165bf
142.6 kB Preview Download